HCW Biologics Regains Full Nasdaq Listing Compliance: Key Details for Investors

Summary of Key Points

• Nasdaq Compliance Regained: HCW Biologics Inc. has regained compliance with all continued listing rules for the Nasdaq Capital Market, as confirmed by the Nasdaq Hearings Panel on February 26, 2026.
• Access to Capital Markets Maintained: This compliance enables HCW Biologics to continue accessing public markets for critical capital to fund its R&D and clinical programs.
• Clinical Pipeline Progress: The company is advancing several proprietary, first-in-class immunotherapeutic drugs targeting autoimmune diseases, cancer, and age-related/senescence-associated diseases.
• Ongoing and Upcoming Clinical Trials: Lead program HCW9302—an IL-2 fusion molecule for autoimmune diseases—is in a Phase 1 study for alopecia areata, initiated in November 2025 (NCT07049328).
• Business Development Progress: HCW Biologics has already entered into two licensing agreements for its proprietary molecules, enhancing its strategic partnerships and potential non-dilutive funding.

Details Investors Should Know

Regaining Nasdaq Compliance: The company’s announcement that it has regained compliance with all Nasdaq Capital Market continued listing rules is highly significant. Previously, HCW Biologics was not in compliance, which could have led to delisting and a severe impact on share liquidity and valuation. With this compliance, the company is now eligible to remain listed, which supports investor confidence and continued access to the capital markets.

CEO Statement: Dr. Hing C. Wong, Founder and CEO, emphasized the company’s gratitude for the Nasdaq Panel’s discretion, which allowed HCW Biologics the time needed to regain compliance with the Equity Rule. He highlighted that this milestone means the company can continue raising capital to advance its innovative immunotherapeutic drugs, which are targeted at fundamentally transforming treatments for autoimmune diseases, cancer, and other age-related diseases.

Clinical Pipeline & Programs:

• HCW9302: The lead product for the autoimmune program is HCW9302, a subcutaneously injectable, first-in-kind interleukin-2 (IL-2) fusion molecule built using the company’s proprietary TOBI™ platform. It is currently in a Phase 1 clinical trial for alopecia areata (NCT07049328), which began in November 2025.
• Additional Pipeline:
  • HCW11-018b (“Big BiTE”): A tetra-valent T-cell engager designed to overcome challenges associated with traditional bi-specific T-cell engagers (BiTE), such as manufacturability, safety, and efficacy against solid tumors.
  • HCW11-040: A pembrolizumab-based, tetra-valent immune checkpoint inhibitor with added functionalities to neutralize immunosuppressive cytokine TGF-β and activate effector immune cell responses, aiming for improved efficacy over existing checkpoint inhibitors.

Business Development and Licensing: The company’s strategy includes business development and strategic licensing. To date, it has entered two licensing agreements, granting exclusive, worldwide rights for certain proprietary molecules. These agreements may provide non-dilutive funding and validate the company’s technology.

Forward-Looking Statements & Risks: The company cautions that forward-looking statements are subject to significant risks and uncertainties. These include, but are not limited to, the development and commercialization of its pipeline products, the ability to raise additional funds, and other market and regulatory risks as described in their SEC filings. Investors should review the company’s risk factors in the latest 10-K and 10-Q filings.

Potential Impact for Shareholders

• Price-Sensitive Event: Regaining compliance with Nasdaq listing requirements is a material event that removes a significant risk overhang and may positively affect share value by maintaining liquidity, market access, and investor confidence.
• Pipeline Progress: Advancement and expansion of the clinical pipeline, including ongoing and planned clinical trials, represent catalysts that could drive future value.
• Licensing Deals: The company’s ability to secure licensing agreements may generate revenue and validate the commercial potential of its platform technologies.

Contact Information

For further investor information, contact:
Rebecca Byam
Chief Financial Officer, HCW Biologics Inc.
Email: [email protected]

Disclaimer

This article is for informational purposes only and should not be considered as investment advice. All forward-looking statements are subject to risks and uncertainties as described in HCW Biologics’ filings with the SEC. Investors should conduct their own due diligence prior to making any investment decisions.

View HCW Biologics Inc. Historical chart here